Cancer-fighting biotech startup Indapta lands $30M with assist from FDA

Seattle-area company Indapta Therapeutics has triggered round two of the $60 million Series A round raised in January 2022. The company received Food and Drug Administration (FDA) approval to begin phase 1 trials for its cell therapy aimed at cancer.

The company currently has 10 employees and plans to add between five and 10 more over the next year. Additionally, the company works with 10-15 consultants on their “natural killer cells” that have the ability to fight cancer.

“Given the current very challenging funding environment, we are running very lean,” CEO Mark Frohlich said. “My goal clearly is to build part of the clinical team and the executive management team here in Seattle.”

READ THE STORY at Puget Sound Business Journal »